Become a Fan. You'll get emails whenever I post articles on OpEdNews
Following graduate and medical school where he earned his MD and PhD degrees, Mark Thornton completed a Clinical Pharmacology Fellowship and received an MPH degree at Johns Hopkins School of Public Health. He has spent 16 years in the development arena, including six years at the FDA and 10 years in the pharmaceutical industry. He is currently Senior Vice-President for Clinical and Regulatory Affairs at GenVec, Inc. in Gaithersburg, Maryland attempting to develop a novel anti-cancer therapy. In addition to his practical experience in development in industry and at the FDA, following his experience as a parent of a child treated for a rare cancer, he became a leading advocate for bipartisan reform in rare cancer policy, and has published in the Wall Street Journal on policy issues inhibiting innovation in cancer development. Most recently he has lead efforts to have specific guidance developed at FDA that would streamline regulatory approvals for for rare cancer indications. Thornton serves on several nonprofit boards, including the conservative Center for Medicine in the Public Interest and the liberal Cancer Leadership Council.